Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 7/20 | 0.56 |
| ▸ | TOP2B | Q02880 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980928 | 0.94 | TOP2A (0.62) | TOP2ATOP2BMEN1NPC1GAA | |
| SCHEMBL3984146 | 0.86 | TOP2A (0.52) | TOP2ATOP2BMEN1NPC1GAA | |
| SCHEMBL3981536 | 0.85 | TOP2A (0.61) | TOP2ATOP2BMEN1NPC1GAA | |
| SCHEMBL3980933 | 0.85 | TOP2A (0.58) | TOP2ATOP2BMEN1NPC1GAA | |
| SCHEMBL3984733 | 0.85 | TOP2A (0.52) | TOP2ATOP2BMEN1NPC1GAA | |
| SCHEMBL3986033 | 0.85 | TOP2A (0.60) | TOP2ATOP2BMEN1NPC1GAA | |
| SCHEMBL3986028 | 0.85 | TOP2A (0.61) | TOP2ATOP2BMEN1NPC1GAA | |
| SCHEMBL6545808 | 0.83 | TOP2A (0.58) | TOP2ATOP2BKDM1A | |
| SCHEMBL5438138 | 0.83 | TOP2A (0.58) | TOP2ATOP2BKDM1A | |
| SCHEMBL3980219 | 0.83 | TOP2A (0.60) | TOP2ATOP2BMEN1NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1380574-B1 | 9-aminoacridine derivates and process for the preparation thereof | SAMJIN PHARM CO LTD (KR) | 2009-05-20 | — | — | EP | disclosed |
| EP-1380574-A1 | 9-aminoacridine derivates and process for the preparation thereof | Samjin Pharmaceutical Co., Ltd. (KR) | 2004-01-14 | — | — | EP | disclosed |
| US-6620936-B2 | Antitumor agents, topoisomerase inhibitors, notoxic | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-09-16 | — | — | US | disclosed |
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2002-08-15 | — | — | US | disclosed |
| EP-1062207-A1 | 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000037447-A1 | 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | ALKBH1, ADCY9, CCR9 | TOP2A 1105/4885TOP2B 841/4885MEN1 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.